ClinicalTrials.gg
TerminatedNCT07274774Updated Nov 18, 2026

SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma

A Phase 2 interventional study of Systemic therapy and Radiotherapy in Hepatocellular Carcinoma and BCLC Stage C Hepatocellular Carcinoma, sponsored by Shandong Cancer Hospital and Institute. Terminated at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Shandong Cancer Hospital and Institute · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Poor accrual
Updated Nov 18, 2026Now TerminatedNow Suspended+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,314 studies in Carcinoma, Hepatocellular with a site in China — 489 open to participants now, 561 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Enrollment
1,011th of 1,038
2 · median 77
Started
2025
with 122 others
Phase 2
333 of 1,314
146 open now
Registered
1,170th of 1,314
by date

Among the 1,314 studies in Carcinoma, Hepatocellular with a site in China, this one is the 1,011th largest by enrollment of the 1,038 interventional ones that give a count, is one of 123 that started in 2025, is one of 333 in phase 2, and was the 1,170th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

489 of the 1,314 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

484 more — sign in →

All 489 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,314 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

This prospective, multicenter, phase II randomized controlled trial compares the efficacy and safety of SBRT combined with systemic therapy versus systemic therapy alone in BCLC stage C hepatocellular carcinoma (HCC). The primary objective is to compare overall survival (OS) between the two arms. Secondary objectives include progression-free survival (PFS), objective response rate (ORR), quality of life (QoL), and incidence and severity of adverse events (AEs). Eligible patients will be randomized 2:1 to an experimental arm (SBRT + systemic therapy) or control arm (systemic therapy alone). Key inclusion criteria include BCLC C disease, Child-Pugh A-B liver function, ECOG ≤2, measurable disease per RECIST 1.1, and stable intrahepatic disease after initial systemic therapy for ≥3 months when applicable. The trial will also include predefined safety monitoring, QoL assessments (EORTC QLQ-C30 and QLQ-HCC18), and exploratory biomarker analyses.

Read the detailed description

Background: Hepatocellular carcinoma (HCC) is frequently diagnosed at advanced stages with limited curative options. Systemic therapies (targeted agents and immune checkpoint inhibitors) have improved outcomes in BCLC C patients, but their therapeutic effect is unsatisfactory. SBRT provides precise high-dose local control and may synergize with systemic therapy by enhancing tumor immunogenicity and improving local disease control.

Study design: Prospective, randomized, open-label, multicenter Phase II trial. In the experimental arm, patients will continue the guideline-recommended systemic treatment received prior to enrollment, in accordance with approved labels and national guidelines, combined with SBRT delivered to portal vein tumor thrombus (PVTT, if present) and/or limited extrahepatic metastatic lesions. In the control arm, patients will continue the same guideline-recommended systemic treatment without SBRT.

Endpoints: The primary endpoint is overall survival (OS). Secondary endpoints include progression-free survival (PFS), objective response rate (ORR by RECIST 1.1 and mRECIST), disease control rate (DCR), duration of response (DoR), quality of life (EORTC QLQ-C30 and QLQ-HCC18), and safety (CTCAE v5.0). Exploratory endpoints may include biomarker dynamics (e.g., immune cell infiltration, viral markers) and patterns of progression.

Safety and monitoring: AEs will be collected from consent through 30 days after the last radiotherapy; SAEs will be reported per protocol (including deaths up to 90 days after radiotherapy). Regular imaging and clinical assessments will monitor efficacy and safety. Data management and monitoring will follow GCP.

03

Conditions studied

  • Hepatocellular Carcinoma
  • BCLC Stage C Hepatocellular Carcinoma

Keywords

  • hepatocellular carcinoma
  • BCLC stage C
  • metastasis
  • radiotheraphy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-70 years.
  2. Histologically or clinically diagnosed HCC per national guidelines.
  3. BCLC stage C (CNLC IIIA/IIIB), including PVTT and/or extrahepatic amenable to protocol procedures.
  4. class A or B (score ≤7).
  5. At least one per 1.1 (criteria specified).
  6. ≤2.
  7. Expected survival ≥6 months.
  8. Adequate organ function per protocol thresholds.
  9. For experimental arm candidates: active lesion count (when PET-CT used) ≤10.
  10. If prior initial systemic therapy given: intrahepatic disease stable ≥3 months.
  11. Effective from consent through 1 year after treatment end.
  12. Ability to understand and sign consent.

Exclusion criteria

Exclusion Criteria:

  1. Second primary (exceptions apply).
  2. Tumor thrombus/ judged not amenable to radiotherapy.
  3. Prior systemic anticancer therapy for current HCC (prior local therapy permitted per rules).
  4. Severe organ dysfunction precluding treatment.
  5. Uncontrolled comorbidities (e.g., uncontrolled diabetes, active peptic ulcer, severe cardiopulmonary disease).
  6. Active uncontrolled infection or active disease requiring systemic therapy.
  7. Significant neurologic dysfunction.
  8. Pregnant or breastfeeding women; no effective .
  9. Known to planned drugs.
  10. Any other condition making participation unsuitable per investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Treatment

    SBRT + Systemic Therapy

    Drug: Systemic therapy · Radiation: Radiotherapy

  • Other
    Control

    Systemic therapy will consist of the continuation of the guideline-recommended systemic treatment received prior to enrollment, in accordance with approved labels and national guidelines.

    Drug: Systemic therapy

Interventions

  • DrugSystemic therapy

    Systemic therapy will consist of the continuation of the guideline-recommended systemic treatment received prior to enrollment, in accordance with approved labels and national guidelines

  • RadiationRadiotherapy

    portal vein tumor thrombus (PVTT, if present) and/or limited extrahepatic active lesions. For patients presenting with more than 10 lesions at baseline (including extrahepatic metastases with or without portal vein tumor thrombus), a comprehensive FDG-PET/CT reassessment of the whole body is required after 3 months of systemic therapy. Patients who demonstrate ≤10 active lesions at this reassessment may then be considered eligible for SBRT. Dose and fractionation: total dose 25-40 Gy delivered in 5 fractions (5-8 Gy per fraction). Dose selection individualized based on tumor size, location and nearby organ-at-risk constraints; sequential or staged SBRT allowed.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time from date of randomization to date of death from any cause

    Time frame: subjects will be followed up for a minimum combined accrual + follow-up period of 48 months (24-month enrollment + 24-month follow-up planned)

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Time from randomization to radiographic disease progression per RECIST 1.1/mRECIST or death

    Time frame: 2 years

  2. Objective Response Rate (ORR)

    proportion achieving CR or PR by RECIST 1.1 and mRECIST; assessed at scheduled imaging

    Time frame: 2 years

  3. Disease Control Rate (DCR)

    proportion achieving CR + PR + SD

    Time frame: 2 years

  4. Duration of Response (DoR)

    from first documented CR/PR to progression or death

    Time frame: 2 years

  5. Quality of Life (QoL)

    baseline and every 3 months using EORTC QLQ-C30

    Time frame: 3 years

  6. Quality of Life (QoL)

    baseline and every 3 months using EORTC QLQ-HCC18

    Time frame: 3 years

  7. Treatment-Related Adverse Events (AEs)

    from consent through 30 days after last radiotherapy (Serious Adverse Event reporting up to 90 days post-radiotherapy)

    Time frame: 3 months

Other outcomes

  1. Patterns of Failure (exploratory)

    description of local vs distant progression and subsequent treatments.

    Time frame: 2 years

  2. Biomarker (exploratory): Hepatitis B Virus DNA Level

    Quantitative assessment of HBV DNA in peripheral blood as a marker of viral replication.

    Time frame: 2 years

  3. Biomarker (exploratory): Alpha-fetoprotein (AFP) Level

    Serum AFP concentration measured as a tumor burden indicator.

    Time frame: 2 years

  4. Biomarker (exploratory): Circulating Tumor DNA (ctDNA) Level

    Quantification of tumor-derived DNA fragments in peripheral blood using next-generation sequencing.

    Time frame: 2 years

  5. Biomarker (exploratory): Peripheral Immune Cell Subsets

    Flow cytometry-based analysis of circulating immune cell populations

    Time frame: 2 years

  6. Biomarker (exploratory): ALBI grade

    ALBI grade assessed as indicators of survival

    Time frame: 2 years

07

Study locations

1 site
  • Shandong Cancer Hospital and Institute
    Jinan, Shandong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2025 to primary completion in Oct 2026, 10 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Nov 2027 → Oct 2026 and completion Nov 2028 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2025
First posted
Dec 10, 2025
StartActual
Nov 30, 2025
Primary completionActual
Oct 16, 2026was Nov 2027
CompletionActual
Oct 18, 2026was Nov 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Suspended→Terminated Poor accrual
changed Oct 15, 2026 · changed Nov 18, 2026
Primary completion
Nov 10, 2027→Oct 16, 2026 (actual)
Nov 18, 2026
Study completion
Nov 10, 2028→Oct 18, 2026 (actual)
Nov 18, 2026
Enrollment
184 (estimated)→2 (actual)
Nov 18, 2026
Show all 2 updates
  1. Nov 18, 2026
    Suspended→Terminated
    Why stopped Poor accrual
    Primary completion Nov 10, 2027→Oct 16, 2026 (now actual)
    Study completion Nov 10, 2028→Oct 18, 2026 (now actual)
    Enrollment 184 (estimated)→2 (actual)
    + 1 other change: verification date
  2. Oct 15, 2026
    Recruiting→Suspended
    Why stopped Difficult to recruit patients
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07274774
Responsible party
Jinbo Yue (Director of Department Radiation Oncology, Shandong Cancer Hospital and Institute) — Principal investigator
First posted
Dec 10, 2025
Start date
Nov 30, 2025
Primary completion
Oct 16, 2026
Completion
Oct 18, 2026
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion